Genmab A/S (OTCMKTS:GNMSF - Get Free Report) crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $208.18 and traded as low as $205.00. Genmab A/S shares last traded at $205.00, with a volume of 60 shares.
Genmab A/S Stock Down 3.2%
The stock's 50 day moving average price is $208.10 and its two-hundred day moving average price is $205.80. The firm has a market capitalization of $13.12 billion, a price-to-earnings ratio of 13.41 and a beta of 0.91.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $3.05 EPS for the quarter, topping analysts' consensus estimates of $1.88 by $1.17. The business had revenue of $765.14 million for the quarter, compared to analyst estimates of $761.09 million. Genmab A/S had a return on equity of 19.23% and a net margin of 35.11%.
Genmab A/S Company Profile
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
